Scientific Literature & Evidence Summary

The Document That Tells Your Safety Story

Founder & CEO, CE Group of Companies  |  Forbes Business Council Member

Regulatory Affairs Expert | Clinical Trials Advisor | Medtech & Food Regulatory Consultant

Science Without Narrative Is Not Communication

Section F is where your dossier transitions from a collection of data to a coherent scientific argument. Raw study reports, CoA data, and regulatory approval documents are necessary — but they do not tell the Scientific Panel what conclusion to draw. Section F does.

The Safety Executive Summary at the heart of Section F is the single most strategically important document in your NSF dossier. It is what the Panel reads before anything else. Its quality — the clarity of the safety narrative, the honesty with which it addresses adverse findings, the rigour of its risk characterisation — directly determines how quickly the Panel moves to detailed review and how many queries are generated.

A well-written Executive Summary from a qualified regulatory scientist is not a commodity document. It requires scientific judgement, regulatory knowledge, and communication skill. It is also not a template that can be filled in with your ingredient’s name. This article explains what it needs to contain and how to build it.

Section F Document Checklist

#	Document	Format	Expert Note
F1	Structured literature review — safety and efficacy studies	Tabulated summary + full texts as per FSSAI’s prescribed formats	Minimum 10–15 key studies. Systematic reviews and meta-analyses carry most weight. Include both supporting and contrary findings.
F2	Full-text copies of all cited studies	PDF attachments	Do not submit abstracts only. Panel may request full texts not submitted — provide proactively.
F3	Safety Executive Summary — structured scientific narrative	Stand-alone document,	The gateway document. Panel reads this first. Quality determines review speed. Written by qualified regulatory scientist — not a generic template.
F4	Risk characterisation document —exposure assessment, risk characterisation	Structured per Codex risk analysis framework	Demonstrates regulatory sophistication. Explicitly maps Section D and E evidence to a defensible safety conclusion.
F5	Evidence grading table — GRADE or similar framework applied to clinical studies	Table within Executive Summary	Not mandatory but strongly recommended. Signals to the Panel that you have assessed evidence quality, not just assembled papers.

 Table 1

The Literature Review — Completeness and Balance Are Both Required

What to Include

The literature review for Section F should identify and summarise all peer-reviewed published studies relevant to the safety of your ingredient or product. This includes human clinical studies (covered in detail in the safety data section), animal toxicology studies, in vitro mechanistic studies, epidemiological data, and post-market surveillance reports.

Include a minimum of 10–15 key studies in your tabulated summary. For well-studied ingredients, the published literature runs to hundreds of papers — in this case, prioritise systematic reviews, meta-analyses, and the highest quality RCTs, with a complete bibliography of all studies reviewed provided as an appendix.

Include Contrary Findings

This is the element most applicants avoid — and it is the one that most undermines Panel confidence when omitted. If published studies report adverse effects, tolerability concerns, or drug interactions for your ingredient, include them in the literature review. Acknowledge the findings, provide their context (dose, population, study design limitations), and explain why they do not represent a safety risk at your proposed conditions of use.

A Panel that finds adverse event literature in its own database search that was not addressed in your submission will query it — and will note that the applicant did not disclose it. Transparency is not a weakness in a regulatory submission. Omission of adverse findings is.

 

The Safety Executive Summary — Structure and Content

Opening Statement

Begin with a clear, unambiguous statement of what the ingredient is, its proposed use in India, and the proposed daily intake at recommended conditions of use. This single paragraph sets the context for everything that follows. The Panel should be able to read the opening and immediately understand what they are being asked to approve.

Genotoxicity Conclusion — Lead With It

The genotoxicity conclusion should appear early in the Executive Summary — ideally in the second or third paragraph. Use the formats as specified by the Food authority for compiling the information/ studies. State affirmatively that the full genotoxicity battery (Ames test, in vitro micronucleus or chromosomal aberration test) has been completed under GLP conditions, and that the results demonstrate no mutagenic or clastogenic potential. If any equivocal result was observed and resolved by in vivo testing, state this and the outcome.

Leading with genotoxicity gives the Panel confidence that the most fundamental safety question — does this substance damage DNA — has been definitively addressed.

NOAEL, ADI, and Safety Margin

Present the NOAEL from the sub-chronic study, the uncertainty factor applied and its justification, the calculated ADI, the Indian EDI, and the resulting safety margin in a clear, structured format. The safety margin calculation (ADI ÷ EDI) should be presented as a ratio — for example, ‘The safety margin at the proposed Indian daily intake of Xmg is 180-fold, well above the minimum 100-fold threshold for novel ingredients.
Do not leave this calculation to the Panel. State it explicitly. A Panel that has to derive the safety margin from disparate data elements across multiple sections of the dossier will take longer — and may calculate it differently from how you intended.

Human Clinical Safety Summary

Summarise the clinical evidence in a structured table as per the formats specified by FSSAI: study reference, Nature of study, Material tested and their levels, Nature of volunteers / subjects / Design of study, Inclusion exclusion criteria, Duration of study, Variables measured, Results obtained,, adverse events, serious adverse events. Follow the table with a brief narrative that draws the conclusion: across X subjects in Y studies over periods of Z weeks to Z months, the ingredient was well tolerated at doses up to X mg/day, with no clinically significant adverse effects. State explicitly if any dose-dependent effects were observed and at what doses.

Transparent Acknowledgement of Limitations

Every safety dataset has limitations. Long-term chronic toxicity data may not be available. Human studies may have been conducted in non-Indian populations. The available evidence may be predominantly from one sex or age group. Acknowledge these limitations in the Executive Summary and explain why they do not undermine the overall safety conclusion. A Panel that sees its own concerns pre-empted and addressed in the summary is less likely to generate queries about them.

The Safety Conclusion

Close the Executive Summary with a clear, unambiguous safety conclusion: ‘Based on the totality of the evidence presented — including genotoxicity assessment, 90-day sub-chronic toxicity study, human clinical safety data across X subjects, and international regulatory approvals in Y jurisdictions — [ingredient/product] is concluded to be safe for consumption at the proposed conditions of use by Indian adults at a daily intake of X mg/day.

This conclusion should be the logical destination of every element that preceded it. If the Panel reads the conclusion and finds it inconsistent with the data presented, queries will follow.

Risk Characterisation — Elevating Your Dossier Above the Standard

The Risk Characterisation Document  is not a mandatory FSSAI requirement — but submitting one is a mark of regulatory sophistication that experienced Panels notice and appreciate. Structured per the Codex Alimentarius risk analysis framework, it formally maps the four risk assessment components — hazard identification, hazard characterisation, exposure assessment, risk characterisation — to your specific evidence set and draws the risk management conclusion.

For applicants with strong international safety evidence and experienced regulatory teams, a well-prepared Risk Characterisation Document can substantially accelerate Panel review. It signals that the applicant understands the scientific framework within which the Panel operates — and has done much of the Panel’s analytical work for them.

Conclusion

A well-prepared Safety Executive Summary, supported by balanced literature, transparent risk assessment, and clear safety conclusions, helps the Scientific Panel evaluate your ingredient efficiently and confidently. By presenting the totality of evidence, including strengths, limitations, and safety margins, applicants demonstrate both scientific rigor and regulatory maturity. Ultimately, a strong Safety executive summary does not just document safety, it builds confidence in the science behind your product.